Clinical Trial: Saruparib in HRDsig+ Solid Tumors

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07832630) titled 'Saruparib in HRDsig+ Solid Tumors' on Sept. 03.

Brief Summary: The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational FoundationOne(R)CDx clinical trial assay.

Study Start Date: Nov. 01

Study Type: INTERVENTIONAL

Condition: Malignant Neoplastic Disease (Disorder)

Intervention: DRUG: Saruparib

Saruparib (AZD5305) 60mg PO daily

DIAGNOSTIC_TEST: FoundationOne(R)CDx

Tumors will be tested for positive HRDsig tumor by the investigational FoundationOne(R)CDx clinical tria...